Ifosfamide cardiotoxicity in humans

Kandylis, Kostas; Vassilomanolakis, M.; Tsoussis, S.; Efremidis, Anna

doi:10.1007/bf00257451

Cited by 47 publications

(25 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…110 Ifosfamide is an alkylating drug that can also induce acute dose-related cardiac complications, such as arrhythmias and heart failure. 111 Because ifosfamide and cyclophosphamide have similar structures, cardiotoxicity may occur by analogous mechanisms. Except for the apparent lack of hemorrhagic myocarditis in ifosfamide-treated patients, the morphological alterations induced by the 2 compounds appear to be similar.…”

Section: Dysfunctionmentioning

confidence: 99%

Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

Lipshultz¹,

Adams²,

Colan³

et al. 2013

Circulation

502

436

View full text Add to dashboard Cite

Section: Dysfunctionmentioning

confidence: 99%

Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

Lipshultz¹,

Adams²,

Colan³

et al. 2013

Circulation

502

436

View full text Add to dashboard Cite

“…80 Infrequently, cardiovascular side effects from a particular drug occur in a specific subset of cancer patients; examples are cardiovascular complications from cisplatin only in patients with metastatic testicular cancer, 18 episodes of cardiotoxicity from low-dose ifosfamide being more common in patients with lymphoma, 81 and alemtuzumab being associated with LV dysfunction in patients with mycosis fungoides. 82…”

Section: Risk Factors For Developing Cardiovascular Complicationsmentioning

confidence: 99%

Cardiovascular Complications of Cancer Therapy

et al. 2004

View full text Add to dashboard Cite

Abstract-The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factors such as the molecular site of action, the immediate and cumulative dose, the method of administration, the presence of any underlying cardiac condition, and the demographics of the patient. Moreover, toxicity can be affected by current or previous treatment with other antineoplastic agents. Cardiotoxic effects can occur immediately during administration of the drug, or they may not manifest themselves until months or years after the patient has been treated. In this article we review commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity. Further research will be required to more accurately predict which patients are at risk for developing cardiotoxicity. In addition, management plans, as well as strategies to reduce cardiotoxicity, need to be developed.

show abstract

“…8,25 HD ifosfamide cardiotoxicity is reported in only two studies more than 20 years old. 56,57 Anecdotal evidence is reported for HD carmustine-associated cardiac toxicity. 58 Recently, nonmyeloablative transplant regimens have been developed to exploit the graft-versus-tumor effect of allogeneic T-cell chimerism while reducing the toxicities associated with myeloablative conditioning.…”

Section: Other Chemotherapeutic Agentsmentioning

confidence: 99%

Cardiac toxicity of high-dose chemotherapy

Morandi

Ruffini

Benvenuto

et al. 2004

Bone Marrow Transplant

150

104

View full text Add to dashboard Cite

Summary:Cardiac toxicity is an uncommon but potentially serious complication of high-dose (HD) chemotherapy and little is known about incidence, severity and underlying mechanisms. We have systematically reviewed the literature of the last 30 years to summarize and appraise the published evidence on cardiac toxicity associated with HD chemotherapy. HD cyclophosphamide-containing regimens have been most commonly associated with cardiac toxicity, with a progressively decreasing incidence over time. Dosage, application regimens and coadministration of other chemotherapeutic agents emerged as risk factors. While cardiac toxicity has been rarely associated with other cytotoxic drugs, an unexpected incidence of severe cardiotoxicity resulted from reduced-intensity conditioning regimens containing melphalan and fludarabine. Predictive value of cardiologic examination of patients is limited, and patients with a slight depression of cardiac performance could tolerate HD chemotherapy. Clinical examination, resting electrocardiography and dosage adjustment in overweight patients remain the mainstay of prevention, with bidimensional echocardiography (2D echo) for patients with a history of anthracycline exposure. Strategies to decrease the long-term negative impact of anthracycline administration on cardiac performance are being investigated. New 2D echo-based techniques and circulating markers of cardiac function hold promise for allowing identification of patients at high risk for and early diagnosis of cardiac toxicity.

show abstract

Ifosfamide cardiotoxicity in humans

Cited by 47 publications

References 3 publications

Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

Cardiovascular Complications of Cancer Therapy

Cardiac toxicity of high-dose chemotherapy

Contact Info

Product

Resources

About